ICDM 2025

Special scientific session 1 (Sponsored by boehringer-ingelheim / Bayer) SGLT2i and the novel MRA: are there synergistic effects or not? Chair(s): Moon-Kyu Lee, Jihyun Lee
Friday 26 September, 08:40~10:00
Room 5
(Art Hall, 4F)

This session explores the potential synergistic effects of SGLT2 inhibitors and novel mineralocorticoid receptor antagonists (MRAs) in cardiorenal protection.
David Cherney will highlight key findings from the EMPA-Kidney trial, Boyeon Kim will share practical insights from Asian clinical experience with finerenone,
and Jennifer B. Green will present data from the CONFIDENCE trial investigating the combined use of finerenone and empagliflozin.

SSS1-L1 David CherneyUniversity of Toronto, Canada: Lessons from the EMPA-kidney trial

SSS1-L2 Jae-Han JeonKyungpook National University, Korea: Practical insights from the experience of finerenone in Asian patients

SSS1-L3 Jennifer B. GreenDuke University, USA: Combination effect of fInerenone and empagliflozin - CONFIDENCE trial

Special scientific session 2 (Sponsored by Daewoong / Dong-A ST / Celltrion) Let’s figure out the best option against diabetes Chair(s): Dong Sun Kim, Seungjoon Oh
Friday 26 September, 13:30~14:50
Room 5
(Art Hall, 4F)

This session explores the pharmacologic differences among SGLT2 inhibitors and their clinical implications, followed by a discussion on their combination with DPP-4 inhibitors or TZDs. Emphasis will be placed on optimizing glycemic control through synergistic dual therapy. By integrating mechanistic and comparative insights, this session aims to inform more effective and individualized treatment strategies for patients with type 2 diabetes in real-world clinical settings.

SSS2-L1 Eun Young LeeThe Catholic University of Korea, Korea: Are all SGLT2 inhibitors the same? – from a basic to clinical standpoint

SSS2-L2 Sang Youl RheeKyung Hee University, Korea: Which one is the best partner? - in view of SGLT2i with DPP-4i

SSS2-L3 Ji Yoon KimSungkyunkwan University, Korea: Which one is the best partner? - in view of SGLT2i with TZD

Special scientific session 3 (Sponsored by AstraZeneca / Novo Nordisk) Intensify, simplify and optimize type 2 diabetes treatment Chair(s): Chang Beom Lee, Kang Seo Park
Friday 26 September, 15:00~16:20
Room 5
(Art Hall, 4F)

This session will explore strategies to intensify, simplify, and optimize treatment for type 2 diabetes using evidence-based, patient-centered approaches. Topics include early intensive therapy with simplified regimens, the clinical benefits of once-weekly GLP-1RAs, and a comparative analysis of dapagliflozin and semaglutide for diabetic kidney disease. By integrating these insights, the session aims to support more effective and streamlined diabetes care.

SSS3-L1 Gyuri KimSungkyunkwan University, Korea: Early, simplified intensive therapy

SSS3-L2 TBDTBD: TBD

SSS3-L3 Hye Jin YooKorea University, Korea: Choice for DKD, dapagliflozin vs. semaglutide

Special scientific session 4 (Sponsored by LG Chem) Best practices for care of diabetes in the elderly Chair(s): Rima T. Tan, Apiradee Sriwijitkamol
Saturday 27 September, 08:40~10:00
Room 5
(Art Hall, 4F)

This session brings together experts from Thailand, the Philippines, and Korea to share current practices and clinical strategies in managing diabetes among older adults across Asia. Specifically, it will present findings from a recent large-scale observational study on Gemigliptin in elderly patients, offering evidence for its therapeutic value and real-world applicability. The session aims to provide practical insights and promote evidence-based practices in geriatric diabetes care throughout the region.

SSS4-L1 Paweena ChunharojrithSiriraj Hospital, Thailand: Current status and advances in diabetes management for the elderly in Thailand

SSS4-L2 Francis PasaporteMetro Iloilo Hospital & Medical Center, Philippines: Diabetes management in the elderly: challenges and solutions in Philippines

SSS4-L3 So Hun KimInha University, Korea: Holistic and personalized strategies for managing type 2 diabetes in elderly

Special scientific session 5 (Sponsored by GSK) Beyond glucose - navigating infections, complications, and prevention in diabetes care (cross-specialty with the Korean society of infectious diseases) Chair(s): Kwan Woo Lee, Hee Jung Choi
Saturday 27 September, 11:00~12:20
Room 5
(Art Hall, 4F)

Beyond glucose shows how people with diabetes face extra risks from infections like shingles and RSV, points out higher disease risks in Asians, and explains benefits of new vaccines. The session will share patient cases, local risk data, and simple prevention steps, stressing why vaccines matter in diabetes care. Participants will leave with strong practical tips to improve patient health and shape the future of diabetes care.

SSS5-L1 Eun-Jung RheeSungkyunkwan University, Korea: Hidden vulnerabilities : infectious diseases in patients with diabetes (clinical cases in shingles, RSV, and beyond)

SSS5-L2 Jung Hwan ParkHanyang University, Korea: Double jeopardy : infections and cardiovascular risks in Asian patients with diabetes

SSS5-L3 Sunghee ParkSoonchunhyang University, Department of Infectious Diseases, Korea: Immunizing against risk : the emerging role of shingles and RSV vaccines in diabetes care (guidelines and vaccine)

구분		사전등록 (~2025년 8월 20일까지)		현장등록 (2025년 9월 25일 ~ 27일)
구분		KDA회원	비회원	KDA회원	비회원
25~27일 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	KRW 280,000	KRW 350,000	KRW 370,000	KRW 450,000
25~27일 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사, 관련분야 교수 및 기타 (군의관 및 공중보건의 포함)	KRW 180,000	KRW 230,000	KRW 250,000	KRW 270,000
One-day 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	KRW 170,000	KRW 210,000	KRW 220,000	KRW 270,000
One-day 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사, 관련분야 교수 및 기타 (군의관 및 공중보건의 포함)	KRW 110,000	KRW 140,000	KRW 150,000	KRW 160,000
저녁 식사	전체	KRW 55,000

Program details

평점안내 (For Korean)